



22nd January 2015

Mucodyne® Paediatric 125mg/5ml (Carbocisteine Oral Liquid) will not be available after April 2015

Dear Health Care Professional,

Sanofi would like to inform you of the following:

- Mucodyne® Paediatric 125mg/5ml (Carbocisteine Oral Liquid) will no longer be available from the end of April 2015. This is because of manufacturing problems.
 - Do not start prescribing Mucodyne® Paediatric 125mg/5ml for new patients.
 - For patients currently on Mucodyne® Paediatric 125mg/5ml consider Mucodyne® 250mg/5ml, if the required dose can be given with this concentration. Use an oral dosing syringe if necessary
- Note that in the summary of product characteristics it is stated that Mucodyne® 250mg/5ml "is not recommended for children. The normal daily dosage is 20 mg/kg bodyweight in divided doses¹."

Indication

Carbocisteine is a mucolytic agent for the adjunctive therapy of respiratory tract disorders characterised by excessive or viscous mucus

Call for reporting adverse drug reactions

Please report suspected adverse drug reactions (ADRs) to this or any other medicine to the Medicines and Healthcare products Regulatory Agency (MHRA) through the Yellow Card Scheme. Please report:

- all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason.
- all suspected ADRs associated with new drugs and vaccines identified by the black triangle ▼

It is easiest and quickest to report ADRs online via the Yellow Cards website:

www.mhra.gov.uk/yellowcard. Alternatively, prepaid Yellow Cards for reporting are available:

- by writing to FREEPOST YELLOW CARD (no other address details necessary)
- by emailing yellowcard@mhra.gsi.gov.uk
- at the back of the British National Formulary (BNF)



- by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789
- or by downloading and printing a form from the Yellow Card section of the MHRA website

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, and product brand name

Company contact point

If you have any questions or require additional information, please contact our **Medical Information**

Department:

- **Tel:** 0845 372 7101
- **E-mail:** UK-medicalinformation@sanofi.com

If you have any questions relating to product stock, please contact **Customer Services:**

- **Tel:** 0800 854 430
- **E-mail:** gb-customerservices@sanofi.com

Yours faithfully,

A handwritten signature in black ink, appearing to be "Timir Patel", written over a light blue horizontal line.

Dr Timir Patel

Commercial Medical Manager

Aventis Pharma Limited (trading as Sanofi)

References:

1. Mucodyne® 250mg/5ml SmPC Januray 2015